India, Sept. 23 -- Jaguar Health, Inc. (JAGX) family company Napo Pharmaceuticals, Inc. on Tuesday announced that the U.S. Food and Drug Administration (FDA) has granted Napo's request for a waiver of the fee associated with the Prescription Drug User Fee Act (PDUFA) for Mytesi (crofelemer delayed-release tablets) for the 2027 fiscal year.
In addition, Jaguar was also granted a waiver of the fee by the Center for Veterinary Medicine of the FDA for the 2027 fiscal year for Canalevia-CA1, Jaguar's conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea in dogs.
The announcement came shortly after Jaguar completed a 1-for-15 reverse stock split designed to help the company regain compliance with Nasdaq's l...